ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Key Developments

• In October 2024, GBI Biomanufacturing and Allterum Therapeutics, biopharmaceutical companies formed a strategic partnership to manufacture 4A10, Allterum's lead monoclonal antibodies targeting CD127, for clinical trials aimed at treating various cancers.
• In March 2024, Lonza, a healthcare manufacturing company, announced the acquisition of Genentech's Vacaville, California manufacturing facility for US$ 1.2 billion, enhancing its large-scale biologics manufacturing capabilities for commercial and clinical mammalian contract projects.
• In February 2024, Samsung Biologics, a contract development and manufacturing organization, partnered with LegoChem Biosciences, a clinical stage biopharmaceutical company, to develop and manufacture Antibody-Drug Conjugates (ADCs) for treating solid tumors, providing antibodies development and drug substance manufacturing services as part of LegoChem’s ADC program.
• In October 2023, Lonza introduced a state-of-the-art Current Good Manufacturing Practices (cGMP) filling line at its Stein, Switzerland facility, designed for the commercial supply of ADCs for a dedicated customer, reinforcing its capabilities in bioconjugate manufacturing.